SCA
AMRI

SAC Capital Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

SAC Capital Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25,400
Closed -$472K – 1387
2014
Q1 		$472K Buy
+25,400
New +$350K ﹤0.01% 1209
2013
Q3 		– Sell
-14,790
Closed -$176K – 2042
2013
Q2 		$176K Buy
+14,790
New +$160K ﹤0.01% 1490

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

SAC Capital Advisors's AMRI Position: Q2 2014 in Review

SAC Capital Advisors sold out of Albany Molecular Research Inc (AMRI) in Q2 2014, closing a stake of 25,400 shares — an estimated $472K sold.

SAC Capital Advisors first reported a position in AMRI in Q2 2013 and held it in 2 quarters. The position peaked at $472K in Q1 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q2 2014.

  • SAC Capital Advisors reported no remaining Albany Molecular Research Inc position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 25,400 Albany Molecular Research Inc shares in Q2 2014, an estimated $472K.
  • SAC Capital Advisors first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Albany Molecular Research Inc position peaked at $472K in Q1 2014.
  • 132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.